ALPS Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-88,339
| Closed | -$95K | – | 1022 |
|
|
2022
Q3 | $95K | Sell |
88,339
-7,771
| -8% | -$8.36K | ﹤0.01% | 1033 |
|
|
2022
Q2 | $163K | Buy |
+96,110
| New | +$163K | ﹤0.01% | 1005 |
|
|
2021
Q4 | – | Sell |
-190,550
| Closed | -$985K | – | 890 |
|
|
2021
Q3 | $985K | Sell |
190,550
-14,225
| -7% | -$73.5K | 0.01% | 390 |
|
|
2021
Q2 | $872K | Sell |
204,775
-75,040
| -27% | -$320K | 0.01% | 419 |
|
|
2021
Q1 | $1.49M | Buy |
279,815
+265
| +0.1% | +$1.41K | 0.01% | 350 |
|
|
2020
Q4 | $1.51M | Buy |
279,550
+82,380
| +42% | +$444K | 0.02% | 346 |
|
|
2020
Q3 | $1.57M | Sell |
197,170
-8,278
| -4% | -$66K | 0.02% | 264 |
|
|
2020
Q2 | $2.06M | Buy |
+205,448
| New | +$2.06M | 0.03% | 234 |
|
|
2018
Q2 | – | Sell |
-125,655
| Closed | -$1.41M | – | 926 |
|
|
2018
Q1 | $1.41M | Buy |
125,655
+21,839
| +21% | +$245K | 0.01% | 256 |
|
|
2017
Q4 | $693K | Buy |
103,816
+11,716
| +13% | +$78.2K | ﹤0.01% | 330 |
|
|
2017
Q3 | $754K | Buy |
92,100
+28,208
| +44% | +$231K | 0.01% | 296 |
|
|
2017
Q2 | $287K | Buy |
63,892
+2,996
| +5% | +$13.5K | ﹤0.01% | 724 |
|
|
2017
Q1 | $336K | Sell |
60,896
-7,128
| -10% | -$39.3K | ﹤0.01% | 676 |
|
|
2016
Q4 | $275K | Buy |
+68,024
| New | +$275K | ﹤0.01% | 676 |
|